Xenon Pharmaceuticals' (XENE) Top Pick Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their top pick rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a report issued on Tuesday, The Fly reports. Several other research analysts have also recently weighed in on XENE. Needham & Company LLC reissued a buy rating and issued a $50.00 price objective on shares of […]

Related Keywords

Canada ,Simon Neil Pimstone ,Simonn Pimstone ,Xenon Pharmaceuticals Inc ,Wells Fargo Company ,Advisors Asset Management Inc ,Analyst Recommendations For Xenon Pharmaceuticals ,Royal Bank ,Xenon Pharmaceuticals ,Cantor Fitzgerald ,Securities Exchange Commission ,Jpmorgan Chase Co ,Institutional Trading Of Xenon Pharmaceuticals ,News Ratings For Xenon Pharmaceuticals Daily ,Xenon Pharmaceuticals Company Profile ,Xenon Pharmaceuticals Trading Down ,Needham Company ,Get Rating ,Moderate Buy ,Pharmaceuticals Trading Down ,Director Simon ,Exchange Commission ,Asset Management ,Xenon Pharmaceuticals Daily ,Nasdaq Xene ,Exene ,Medical ,Reiterated Rating ,